Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disposition of [14C]-LY2835219 Following Oral Administration in Healthy Subjects.

Trial Profile

Disposition of [14C]-LY2835219 Following Oral Administration in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary)
  • Indications Brain cancer; Breast cancer; Cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top